Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS.
TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information.
We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.
TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.
Treatment Action Group
261 Fifth Avenue, Suite 2110
New York, NY 10016-7701
Categories Covered:Tenofovir Disoproxil Fumarate (Viread), HIV Care and Services Outside the US, First-Line HIV Treatment, Switching or Stopping HIV Treatment, HIV Epidemiology, Adverse Events, Comorbidities, and HIV, HIV Treatments in Development, Meeting the Costs of HIV Care, HIV Policy and Advocacy, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Abacavir/Lamivudine (Epzicom, Kivexa), HIV Prevention Methods, HIV Basic Science and Pathogenesis, Efavirenz (Sustiva, Stocrin), HIV Treatment Strategies, PrEP (HIV Pre-Exposure Prophylaxis), Pregnancy, Childbirth, and HIV, Didanosine (ddI, Videx), HIV Case Management and Social Work, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Enfuvirtide (T-20, Fuzeon), Tipranavir (Aptivus), Providing Quality HIV Care, HIV Education and Risk Management, FDA-Approved HIV Medications, HIV, Discrimination, and Law, Emtricitabine (FTC, Emtriva), HIV Testing, Atazanavir (Reyataz), Managing HIV Drug Resistance
"As exemplified by the AZT protests, advocates have long pointed out the injustice of excessive, access-limiting profiteering on treatments developed with public support."
Results from the first human trials of a dual broadly neutralizing antibodies regimen appeared effective, safe, and well tolerated.
Leaders and experts in End the Epidemic planning processes share their perspectives on some of the most common roadblocks.
Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.
The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T-cell counts in the absence of antiretroviral therapy has led them to be proposed as a model for a functional cure of HIV infection.
During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...
There is growing interest in cells considered part of the innate immune system, particularly natural killer (NK) cells. A number of studies have been published that support the idea that NK cells can play an important role in controlling virus replic...
Several recently presented and published studies offer potentially important new data relevant to efforts to identify cells containing latent HIV and target them for elimination.